Works matching Cutaneous T-cell lymphoma (CTCL)

Results: 1318
    1
    2
    3
    4

    Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.

    Published in:
    OncoImmunology, 2017, v. 6, n. 5, p. N.PAG, doi. 10.1080/2162402X.2017.1306618
    By:
    • Litvinov, Ivan V.;
    • Tetzlaff, Michael T.;
    • Thibault, Philippe;
    • Gangar, Pamela;
    • Moreau, Linda;
    • Watters, Andrew K.;
    • Netchiporouk, Elena;
    • Pehr, Kevin;
    • Prieto, Victor G.;
    • Rahme, Elham;
    • Provost, Nathalie;
    • Gilbert, Martin;
    • Sasseville, Denis;
    • Duvic, Madeleine
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13

    miR-155 expression in Primary Cutaneous T-Cell Lymphomas (CTCL).

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2017, v. 31, n. 1, p. e27, doi. 10.1111/jdv.13597
    By:
    • Fava, P.;
    • Bergallo, M.;
    • Astrua, C.;
    • Brizio, M.;
    • Galliano, I.;
    • Montanari, P.;
    • Daprà, V.;
    • Novelli, M.;
    • Savoia, P.;
    • Quaglino, P.;
    • Fierro, M.T.
    Publication type:
    Article
    14

    JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).

    Published in:
    Cancers, 2021, v. 13, n. 2, p. 280, doi. 10.3390/cancers13020280
    By:
    • Vadivel, Chella Krishna;
    • Gluud, Maria;
    • Torres-Rusillo, Sara;
    • Boding, Lasse;
    • Willerslev-Olsen, Andreas;
    • Buus, Terkild B.;
    • Nielsen, Tea Kirkegaard;
    • Persson, Jenny L.;
    • Bonefeld, Charlotte M.;
    • Geisler, Carsten;
    • Krejsgaard, Thorbjorn;
    • Fuglsang, Anja T.;
    • Odum, Niels;
    • Woetmann, Anders
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
    By:
    • Horwitz, S.M.;
    • Scarisbrick, J.;
    • Prince, H.M.;
    • Whittaker, S.;
    • Duvic, M.;
    • Kim, Y.H.;
    • Quaglino, P.;
    • Zinzani, P.L.;
    • Bechter, O.;
    • Eradat, H.;
    • Pinter‐Brown, L.;
    • Akilov, O.;
    • Geskin, L.;
    • Sanches, J.;
    • Ortiz‐Romero, P.;
    • Lisano, J.;
    • Brown, L.;
    • Palanca‐Wessels, M.C.;
    • Gautam, A.;
    • Bunn, V.
    Publication type:
    Article
    40
    41
    42

    FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
    By:
    • Horwitz, S.M.;
    • Scarisbrick, J.;
    • Prince, H.M.;
    • Whittaker, S.;
    • Duvic, M.;
    • Kim, Y.H.;
    • Quaglino, P.;
    • Zinzani, P.L.;
    • Bechter, O.;
    • Eradat, H.;
    • Pinter‐Brown, L.;
    • Akilov, O.;
    • Geskin, L.;
    • Sanches, J.;
    • Ortiz‐Romero, P.;
    • Lisano, J.;
    • Brown, L.;
    • Palanca‐Wessels, M.C.;
    • Gautam, A.;
    • Bunn, V.
    Publication type:
    Article
    43
    44
    45

    RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 245, doi. 10.1002/hon.2438_109
    By:
    • Horwitz, S.;
    • Whittaker, S.;
    • Duvic, M.;
    • Dummer, R.;
    • Kim, Y.H.;
    • Scarisbrick, J.;
    • Quaglino, P.;
    • Zinzani, P.;
    • Wolter, P.;
    • Eradat, H.;
    • Sanches, J.;
    • Ortiz ‐ Romero, P.;
    • Akilov, O.;
    • Trotman, J.;
    • Taylor, K.;
    • Dalle, S.;
    • Weichenthal, M.;
    • Walewski, J.;
    • Fisher, D.;
    • Wang, Y.
    Publication type:
    Article
    46

    PH 1 TRIAL EVALUATING MRG-106, A MICRORNA-155 INHIBITOR, ADMINISTERED BY INTRATUMORAL, SUBCUTANEOUS, OR INTRAVENOUS DELIVERY IN CUTANEOUS T-CELL LYMPHOMA (CTCL) PATIENTS.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 275, doi. 10.1002/hon.2438_149
    By:
    • Querfeld, C.;
    • Foss, F.M.;
    • Porcu, P.;
    • Kim, Y.H.;
    • Pacheco, T.;
    • Haverkos, B.;
    • Halwani, A.S.;
    • DeSimone, J.;
    • William, B.;
    • Pinter ‐ Brown, L.;
    • Seto, A.;
    • Ruckman, J.;
    • Landry, M.;
    • Jackson, A.L.;
    • Dickinson, B.;
    • Sanseverino, M.;
    • Rodman, D.;
    • Rubin, P.;
    • Marshall, W.S.
    Publication type:
    Article
    47
    48

    Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 48, doi. 10.1002/hon.2437_31
    By:
    • Bagot, M.;
    • Porcu, P.;
    • Ram ‐ Wolff, C.;
    • Khodadoust, M.;
    • Basem, W.;
    • Battistella, M.;
    • Marie ‐ Cardine, A.;
    • Vermeer, M.;
    • Mathieu, S.;
    • Whittaker, S.;
    • Duvic, M.;
    • Bensussan, A.;
    • Paturel, C.;
    • Bonnafous, C.;
    • Thonnart, N.;
    • Widemann, A.;
    • Bonin, C.;
    • Sicard, H.;
    • Paiva, C.;
    • Pilz, K.
    Publication type:
    Article
    49
    50